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ABSTRACT Copy number alterations (CNA) are one of the driving mechanisms of glioma tumorigenesis,
and are currently used as important biomarkers in the routine setting. Therefore, we performed CNA
proﬁling of 65 astrocytomas of distinct malignant grades (WHO grade I–IV) of Brazilian origin, using array-
CGH and microsatellite instability analysis (MSI), and investigated their correlation with TERT and IDH1
mutational status and clinico-pathological features. Furthermore, in silico analysis using the Oncomine
database was performed to validate our ﬁndings and extend the ﬁndings to gene expression level. We
found that the number of genomic alterations increases in accordance with glioma grade. In glioblastomas
(GBM), the most common alterations were gene ampliﬁcations (PDGFRA, KIT, KDR, EGFR, and MET) and
deletions (CDKN2A and PTEN). Log-rank analysis correlated EGFR ampliﬁcation and/or chr7 gain with
better survival of the patients. MSI was observed in 11% of GBMs. A total of 69% of GBMs presented TERT
mutation, whereas IDH1 mutation was most frequent in diffuse (85.7%) and anaplastic (100%) astrocytomas.
The combination of 1p19q deletion and TERT and IDH1 mutational status separated tumor groups that
showed distinct age of diagnosis and outcome. In silico validation pointed to less explored genes that may
be worthy of future investigation, such as CDK2, DMRTA1, and MTAP. Herein, using an extensive inte-
grated analysis, we indicated potentially important genes, not extensively studied in gliomas, that could be
further explored to assess their biological and clinical impact in astrocytomas.
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Malignant gliomas are highly invasive tumors that account for70% of
all primary adult brain neoplasms (Louis et al. 2007). Gliomas are
classiﬁed into different histological subtypes, with astrocytomas the
most prevalent. The WHO divides astrocytomas into four malignancy
grades: pilocytic astrocytoma (WHO grade I), diffuse astrocytoma
(WHO grade II), anaplastic astrocytoma (WHO grade III), and GBM
(WHO grade IV) (Louis et al. 2007), the latter responsible for 82% of
the malignant gliomas. GBMs are lethal tumors, presenting a one-year
survival of 35.7%, and a ﬁve-year survival of 4.7% (Omuro andDeAngelis
2013). Clinically, GBM can be subdivided as: primary GBMs (approx-
imately 95% of cases) when they arise de novo and typically manifest
in older patients (peak age at diagnosis between 75 and 84 yr); or
secondary GBMs, responsible for approximately 5% of all GBMs,
which occur in younger patients, and can evolve from a lower-grade
diffuse and/or an anaplastic astrocytoma (Sturm et al. 2014).
These clinical differences also reﬂect distinct genetic pathways;
primary GBMs are characterized by EGFR ampliﬁcation, and loss of
heterozygosity (LOH) of chr10q, deletion of PTEN, and p16, whereas
secondary GBMs are characterized by mutations in TP53, overexpres-
sion of PDGFR, LOH of chr10q, and abnormalities in the p16 and RB
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pathways (Wen and Kesari 2008). Using an integrated genomics ap-
proach, the TCGA (The Cancer Genome Atlas) consortium described
four different subtypes of GBMs (classical, mesenchymal, proneural,
and neural) (Verhaak et al. 2010). Alterations (expression, mutation,
and/or copy number) of the genes TP53, IDH1, PDGFRA, EGFR, NF1,
and CDKN2A were considered the most important events to distin-
guish these four subtypes. Additional analysis of glioma–CpG island
methylator phenotype (G–CIMP) positive and G–CIMP negative tu-
mors has shown that DNAmethylation patterns strongly correspond to
the status of IDH1mutation (Noushmehr et al. 2010). Recently, hotspot
TERT promoter gene mutations have been found in gliomas, with the
highest incidence in GBMs (60%) (Vinagre et al. 2013; Heidenreich
et al. 2014; Killela et al. 2013; Batista et al. 2016). These mutations
generate a de novo binding site for GABPA transcription factor, which
ultimately leads to high TERT expression (Bell et al. 2015). More re-
cently, a large cohort study described ﬁve glioma groups based on 1p/19q
codeletion, IDH1/2 and TERT promoter mutational proﬁle, with impor-
tant clinical impact, with the “triple-negative” group or the only TERT-
mutated group exhibiting a higher mortality risk (Foote et al. 2015;
Eckel-Passow et al. 2015).
Therefore, the aim of this study was to characterize the genomic
proﬁle of 65 Brazilian astrocytomas, using aCGH andMSI, as well as to
associate these data with the mutational status of the TERT promoter
and IDH1 genes, and clinico-pathological features of the patients. Ad-
ditionally, by extending these analyses using in silico approaches, this
study aimed to describe potentially important molecular subgroups
with clinical impact and targets that could be the object of future
investigation.
MATERIALS AND METHODS
Patients
Sixty-ﬁve frozen tissue specimens comprising pilocytic astrocytomas
(n = 7), diffuse astrocytomas (n = 9), anaplastic astrocytomas (n = 7),
and GBMs (n = 41 primary and one secondary GBMs) were evaluated.
Overall, there were 62 primary tumors and three recurrences (with the
matched primary tumor also present in our analysis): one pilocytic
astrocytoma that recurred after the ﬁrst surgery, one diffuse astrocy-
toma that progressed to GBM after the surgery, and one GBM that
recurred.
Histologic review of the slides was performed by two neuropathol-
ogists (A.P.B. and G.C.A.) to conﬁrm the diagnosis, and to select the
samples with . 75% of neoplastic cells and an absence of necrosis.
n Table 1 Clinico-pathological features of astrocytomas
Pilocytic
Astrocytoma
Diffuse
Astrocytoma
Anaplastic
Astrocytoma Glioblastoma
Number of patients 7 9 7 42
Age (years)a 16.7 (9–38) 38.5 (15–70) 35.7 (30–44) 59.4 (25–81)
Sex Male 85.7% 44.4% 42.9% 66.7%
Female 14.3% 55.6% 57.1% 33.3%
Follow up (months)a 39.7 (17–56) 27 (0–58) 36.6 (0–93) 8.5 (0–43)
Karnofsky Performance Status (KPS) , 70 0% 0% 14.3% 28.6%
$ 70 100% 100% 85.7% 59.5%
N/A 0% 0% 0% 11.9%
Surgery type Total resection 42.9% 22.2% 57.1% 47.6%
Partial resection 42.9% 44.4% 14.3% 47.6%
N/A 14.2% 33.4% 28.6% 4.8%
Radiotherapy Yes 0% 22.2% 71.4% 54.8%
No 100% 77.8% 28.6% 45.2%
Chemotherapy Yes 0% 0% 14.3% 26.2%
No 100% 100% 85.7% 73.8%
Status of the patient Alive, free of disease 14.3% 11.1% 0% 0%
Alive, with the disease 85.7% 44.5% 57.1% 16.7%
Death by cancer 0% 33.3% 42.9% 81%
N/A 0% 11.1% 0% 2.3%
N/A, not available.
a
Average (minimum–maximum).
Figure 1 Plots representing the whole genome of (A) pilocytic as-
trocytoma and (B) glioblastoma.
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DNA was isolated from frozen tissue and the peripheral blood of each
patient and used for further analysis. Clinical data for each patient was
obtained, and the summary of the characteristics is shown in Table 1.
The present study was approved by the Barretos Cancer Hospital Ethi-
cal Committee (ID 408/2010).
DNA isolation
TheDNA frompatients’ bloodwas isolated using aQIAmpDNAblood
Mini Kit (Qiagen), and DNA from frozen tumor tissue was isolated
using a DNeasy Blood and Tissue Kit (Qiagen) according to the pro-
tocols provided by the supplier. The 260/280 and 260/230 ratios were
determined byNanoDrop (Thermo Scientiﬁc) and theDNAwas quanti-
ﬁed usingQuant-IT PicoGreen dsDNA (Invitrogen), using the supplier’s
protocol.
Array-CGH
Two-color 60 K array Comparative Genomic Hybridization (aCGH)
was performed using the default protocol published by Agilent Tech-
nologies (AgilentOligonucleotideArray-BasedCGHforGenomicDNA
Analysis Enzymatic Labeling for Blood, Cells, or Tissues, protocol v. 7.2,
published in July 2012) as previously described (Bidinotto et al. 2015).
DNA of each patient’s blood was used as control, in order to exclude
copy number variations. AluI and RsaI restriction enzymes were used
to digest 400 ng of both tumor and blood DNA, which was then in-
cubated with random primers. Blood DNA was labeled with cyanine-3
(Cy3), whereas tumor DNA was labeled with cyanine-5 (Cy5). Equal
quantities of Cy3- and Cy5-labeled DNA was hybridized into Agilent
Human Genome CGH 8 · 60 K microarray slides overnight, and
washed according to the supplier’s default protocol. The slides were
scanned and decoded by the software Feature Extraction v. 10.7 (Agilent
Technologies), using the protocol CGH_107_Sep09. The signal in-
tensities were log2 transformed, and the spots were mapped in the
most recent version of the human genome (hg19). The data were
Lowess normalized and smoothing corrected. The data were CBS
segmented. The low-level copy gains/losses threshold value was consid-
ered 0.1, and the moderate-to-high gene ampliﬁcation/homozygous
deletion threshold value was considered 0.7, in ﬁve consecutive probes.
aCGH data of the 65 Agilent arrays can be accessed using the Gene
Expression Omnibus (GEO) series accession number GSE71538
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE71538).
Bioinformatics analysis
Genome plots of each case were generated and visually inspected. Next,
frequencyplotswere generated, andgenomic regionswere considered as
frequently altered when they were gained or lost in at least 30% of the
same tumor type. Survival analysis was performed to each altered region
found in GBM samples. Kaplan–Meier plots were done considering the
regions statistically signiﬁcant (P , 0.05) in log rank tests. In order to
validate our ﬁndings, we extended our aCGH analysis using publicly
available GBM data on the TCGA Research Network dataset (http://
cancergenome.nih.gov). The set consisted of 498 GBMs CNVMSKCC
level 1 data of the Agilent Human Genome CGH 244K microarray
platform, and it was subjected to the same CNA detection algorithms
performed in our samples.
Genomic regions frequently ampliﬁedordeletedwere considered for
further in silico analysis using the professional version of the compen-
dium of cancer transcriptome proﬁles, Oncomine (Compendia Biosci-
ence, Ann Arbor, MI). Eight GBM expression datasets (totalizing 1489
tumors and brain normal samples) were selected from the Oncomine
database. The expression of potentially relevant genes was analyzed in
these datasets by selecting the genes that were present in frequently
ampliﬁed or deleted regions of our aCGH experiments. The genes
considered relevant presented ampliﬁcation in our experiment and
overexpression in the Oncomine datasets, or homozygous deletion in
our experiment and loss of expression in the Oncomine datasets.
The mRNA expression of these relevant genes was further assessed
on the TCGA Research Network GBM expression dataset (http://
cancergenome.nih.gov, n = 542 GBMs) from the Oncomine database.
The expression of the genes was categorized in terms of positive or
n Table 2 Average number of alterations in aCGH cases
Tumor Type Gains Losses Ampliﬁcations Deletions Total Number of Alterations
Pilocytic astrocytoma 2.6 (0–9) 2.7 (0–11) 0 0.1 (0–1) 5.4 (0–20)
Diffuse astrocytoma 4.7 (0–11) 5.8 (2–12) 0.2 (0–1) 0.1 (0–1) 10.8 (4–22)
Anaplastic astrocytoma 8.0 (1–12) 10.1 (3–21) 0 0 18.1 (11–33)
Glioblastoma 14.0 (0–90) 17.4 (2–61) 1.5 (0–10) 0.9 (0–4) 33.8 (7–164)
Values expressed as average (minimum–maximum) in each case. aCGH, array comparative genomic hybridization.
Figure 2 Heatmap representing the ampliﬁcations, gains, losses, and
deletions detected through aCGH in pilocytic astrocytomas, diffuse
astrocytomas, anaplastic astrocytomas and glioblastomas. aCGH, array
comparative genomic hybridization; LOH, loss of heterozygosity; MSI,
microsatellite instability analysis; MSS, microsatellite stable.
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negative for each patient, based on amedian intensity of log2 median-
centered value. If the intensity value of the gene was greater than the
median value considering the 542GBMs, it was considered positive; other-
wise, the gene was considered negative in the patient. Furthermore, the
expression of each genewas correlated to the overall survival of the patients.
Additionally, correlation studies were performed. The genes were
PCAordered,andPearsoncorrelationcoefﬁcientwasassessedontheTCGA
dataset. Correlations with P, 0.05 were considered statistically signiﬁcant.
Finally, the potentially relevant genes were clustered by biological
importance and canonical pathways, using the DAVID v6.7 bioinfor-
matics tool (TheDatabase forAnnotation,Visualization, and Integrated
Discovery) (Huang et al. 2007).
Microsatellite instability (MSI)
TheMSIanalysisof tumorandbloodDNAof thepatientswasperformed
according to methodology previously published (Viana-Pereira et al.
2011; Campanella et al. 2014, 2015a). Brieﬂy, ﬁve markers (NR27,
NR21, NR24, BAT25, and BAT26) were PCR multiplexed, and the
products were separated using an ABI Prism 3500 genetic analyzer (Life
Technologies). The results were analyzed with GeneScan Analysis soft-
ware, version 3.7 (Life Technologies).
TERT mutation analysis
The hotspot mutations analysis of the TERT promoter gene was per-
formed by PCR followed by direct Sanger sequencing (Vinagre et al.
2013; Campanella et al. 2015b; Batista et al. 2016). Brieﬂy, the TERT
promoter region was ampliﬁed by PCR using the primers: 59-AGTGG
ATTCGCGGGCACAGA-39 (forward) and 59-CAGCGCTGCCTGA
AACTC-39 (reverse), leading to a 235 bp PCR product containing the
C228T and C250T mutations. Ampliﬁcation PCR was performed with
an initial denaturation at 95 for 15 min, followed by 40 cycles of 95
denaturation for 30 sec, 64 annealing for 90 sec, and 72 elongation for
Figure 3 Frequency plot representing the gained and lost regions in glioblastomas.
n Table 3 Most frequently ampliﬁed and deleted regions in glioblastoma samples
Event N Region Genes
Ampliﬁcation 2 4q11-q12 DCUN1D4, LRRC66, SGCB, SPATA18, SCFD2, FIP1L1, LNX1, CHIC2,
GSX2, PDGFRA, KIT, KDR, SRD5A3, TMEM165, CLOCK, PDCL2
Ampliﬁcation 14 7p12.2-p11.2 VWC2, ZPBP, IKZF1, FIGNL1, DDC, GRB10, COBL, POM121L12,
VSTM2A, SEC61G, EGFR, LANCL2, SEPT14, ZNF713, GBAS, PSPH,
CCT6A, SUMF2, PHKG1, CHCHD2
Ampliﬁcation 2 7q31.2 CAV2, CAV1, MET, CAPZA2
Ampliﬁcation 4 12q13.2-q13.3 NEUROD4, OR9K2, OR10A7, OR6C74, OR6C6, OR6C1, OR6C3,
OR6C75, OR6C65, PHC1B, OR6C76, OR6C2, OR6C70, OR6C68,
OR6C4, OR2AP1, OR10P1, METTL7B, ITGA7, BLOC1S1, RDH5,
CD63, GDF11, SARNP, ORMDL2, DNAJC14, MMP19, WIBG, DGKA,
SILV, CDK2, RAB5B, SUOX, IKZF4, RPS26, ERBB3, PA2G4, ZC3H10,
FAM62A, MYL6, SMARCC2, RNF41, OBFC2B, SLC39A5, ANKRD52,
COQ10A, CS, CNPY2, PAN2, IL23A, STAT2, APOF, TIMELESS, MIP,
SPRYD4, GLS2, RBMS2, BAZ2A, ATP5B, PTGES3, NACA, PRIM1
Ampliﬁcation 3 12q14.3-q15 CAND1, DYRK2
Deletion 2 1p32.3 DMRTA2, FAF1
Deletion 20 9p22.1-p21.3 SLC24A2, MLLT3, KIAA1797, PTPLAD2, IFNB1, IFNW1, IFNA21,
IFNA4, IFNA7, IFNA10, IFNA16, IFNA17, IFNA14, IFNA5, KLHL9,
IFNA6, IFNA13, IFNA2, IFNA8, IFNA1, MTAP, C9orf53, CDKN2A,
CDKN2B, DMRTA1, ELAVL2, C9orf134
Deletion 2 10q23.2-q23.31 PAPSS2, ATAD1, PTEN
The genes of potential importance are shown in bold. N, number of GBM cases.
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30 sec, and 72 ﬁnal elongation for 7min. Ampliﬁcation of PCRproducts
was conﬁrmed by gel electrophoresis. Sequencing PCR was performed
using a Big Dye terminator v3.1 cycle sequencing ready reaction kit
(Applied Biosystems) and an ABI PRISM 3500 xL Genetic Analyzer
(Applied Biosystems).
IDH1 mutation analysis
The analysis of hotspot mutations of IDH1 (exon 4) was performed by
PCR followed by direct sequencing. Brieﬂy, the IDH1 region of interest
was ampliﬁed by PCR using the primers: 59-CGGTCTTCAGAGAAG
CCATT-39 (forward) and 59-CACATTATTGCCAACATGAC-39 (re-
verse). An ampliﬁcation PCR reaction was performed in a total volume
of 15 ml, comprising: 1 ml of DNA, 1 · buffer solution, 2 mM MgCl2,
200mMof each dNTP, 0.3mMof each set primer, and 0.5 U Taq DNA
polymerase (Invitrogen), and was performed in a Veriti 96-well Ther-
mal Cycler with an initial denaturation at 95 for 10 min, ampliﬁed for
40 cycles of denaturation at 95 for 45 sec, annealing at 58 for 45 sec,
and extension at 72 for 45 sec, and a ﬁnal extension at 72 for 10 min.
Ampliﬁcation of PCR products was conﬁrmed by gel electrophoresis.
Sequencing PCR was performed using a Big Dye terminator v3.1 cycle
sequencing ready reaction kit (Applied Biosystems) and an ABI PRISM
3500 xL Genetic Analyzer (Applied Biosystems).
Data availability
The authors state that all data necessary for conﬁrming the conclusions
presented in the article are represented fully within the article.
RESULTS
Copy number alterations (CNA)
The number of genomic alterations, detected through aCGH, increased
in accordance with WHO grade. The average number of CNAs per
sample varied from 5.4 in pilocytic astrocytomas (Figure 1A) to 33.8 in
GBMs (Figure 1B). The average number of gains, losses, ampliﬁcations,
and deletions per tumor type is described in Table 2.
The summary of gains, losses, ampliﬁcations, and deletions in all the
samples is found in Figure 2. In pilocytic astrocytomas (WHO grade I),
we detected gain of chr7q34, which was associated with the presence of
the KIAA1549:BRAF gene fusion, as recently reported by our group via
FISH assay on these samples (Becker et al. 2015a). In diffuse astrocyto-
mas (WHO grade II), the most frequent alterations were gains in
chr7q31.1, chr8q23.3-q24.3, chr14q11.2, and chr17q25.3, and losses in
chr1p36.33-p36.32, 1p35.3, chr19q13.31-q13.43, chrXp22.33-p21.3, and
chrXp11.4-p11.22. In anaplastic astrocytomas (WHO grade III), the
most frequent alterations were gains in chr7q11.23-q35, chr8q21.3-q24.3,
and chr10p15.3-p14, and losses in chr1p36.33-p36.32, chr2q37.1-q37.3,
chr4q35.1-q35.2, chr11p15.5-p15.4, chr13q11-q34, chrXp22.33-p22.31,
and chrXp11.4-p11.2. The overall alterations identiﬁed in GBMs are
summarized in Figure 3. The most recurrent alterations were gain in
chr7p22.3-q36.3, and losses in chr9p24.3-p21.1 and chr10p15.3-q26.3.
Frequent losses were also observed at chr13q11.q34, chr14q11.2, and
chr22q11.1-q13. Ampliﬁcation of the chr7p12.2-p11.2 regionwas found
in 33.3% of the GBMs, and 47.6% of cases exhibited deletion of
chr9p22.1-p21.3. Loss of the 10q23.2-q23.31 region was found in
88.1% of cases. However, only a small fraction (4.8%) presented homo-
zygous deletion, and 31% of the samples presented loss in 1p32.3 (Fig-
ure 3). Due to the high prevalence of alterations, we further evaluated
the candidate genes present in these regions (Table 3).
TERT and IDH1 mutation
From the 65 samples analyzed forTERTmutation, 47.7%weremutated
(33.9% at the c.-124C . T hotspot, and 13.8% at c.-146C . T)
(Figure 2) and 52.3% were wild-type. The percentage of mutated
samples was 14.3% (1/7) in pilocytic astrocytomas, 11.1% (1/9) in
diffuse astrocytomas, 0% (0/7) in anaplastic astrocytomas, and
69.1% (29/42) in GBMs (Supplemental Material, Table S1).
IDH1 mutational status was assessed in 60 samples (ﬁve pilocytic
astrocytomas, nine diffuse astrocytomas, seven anaplastic astrocy-
tomas, and 39 GBMs), and we observed that 17/60 (28.3%) of cases
presented IDH1 mutation. The percentage of mutated samples in
the tumor types was 0% in pilocytic astrocytomas, 77.8% in diffuse
astrocytomas (six presenting Arg132His and one presenting Arg132Cis
mutation), 100% in anaplastic astrocytomas (ﬁve presentingArg132His
and two Arg132Cis mutation), and 7.7% in GBMs (all presenting
Arg132His mutation) (Figure 2 and Table S1).
n Table 4 Microsatellite stability status of the glioma samples
Tumor Type N
MSI Status
MSS + MSI-L MSI-H
Pilocytic astrocytoma 6 6 (100%) 0
Diffuse astrocytoma 8 8 (100%) 0
Anaplastic astrocytoma 5 5 (100%) 0
Glioblastoma 36 32 (88.9%) 4 (11.1%)
N, number of samples analyzed of each tumor type; MSI, microsatellite instabil-
ity; MSS, microsatellite stable; MSI-L, low microsatellite instability; MSI-H, high
microsatellite instability.
Figure 4 Heatmap representing the ampliﬁcations, gains, losses,
and deletions through aCGH, as well as the mutational proﬁle of
TERT and IDH1, of the primary and matched recurrence tumors.
aCGH, array comparative genomic hybridization; LOH, loss of
heterozygosity.
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Microsatellite analysis
MSI status was assessed in 55 cases (Table 4); MSI-Hwas only observed
in four GBMs (11.1%), the remaining samples presentingmicrosatellite
stable or MSI-L phenotypes (Table 4). One MSI case presented a high
number of CNAs (total of 81 CNAs) and TERT mutation. Two other
samples presented TERTmutation, were wild-type for IDH1, and pre-
sented a total of 23 and 24 CNAs, respectively. The remaining sample
was wild-type for TERT and IDH1, and presented 25 CNAs.
Matched primary recurrence tumors
The molecular proﬁle of the matched primary and recurrence tumors
are summarized in Figure 4.
The recurrence of pilocytic astrocytoma presented mutation in
TERT. No other molecular differences were found when the primary
pilocytic astrocytoma was compared to the recurrence (both presented
only chr7q34 gain, with no other gene mutation found).
The primary diffuse astrocytoma presentedmainly chr7, chr8q, and
chr11q gains, aswell as chrXp loss. At recurrence, it progressed toGBM,
withthe typical featuresof this tumor typedescribedabove(ampliﬁcation
of EGFR, gain at chr7, and losses at chr9p24.3-p21.1, chr10p15.3-q26.3,
chr13, and chr22). ChrXp loss and IDH1mutation were found in both
tumors (primary and recurrence).
Finally, the GBM sample that recurred into GBM presented
exactly the same molecular features, being the typical chromosomal
characteristics presented above, and TERT mutated. All these sam-
ples were microsatellite stable.
Clinical impact of the molecular features
Following the criteria recently described (Eckel-Passow et al. 2015), we
separated the cases based on 1p/19q deletion and IDH1 and TERT
promoter mutational status. We found that 1.8% of the cases presented
the three alterations “triple positive,” 22.8% presented mutation only in
IDH1, 49.1% presented mutation only in TERT, and 26.3% did not
present alteration in any of these markers and was considered to be
“triple negative” (Table 5). Of note, survival curves show that the group
of cases with mutation only in TERT presented lower survival than
those presenting only IDH1 mutation (mean survival of 8.5 months
vs. 29.2months, respectively, P = 0.024 in log rank test), whereas “triple
negative” cases presented a mean survival of 21.3 months (Figure 5).
Nonsupervisedhierarchical clusteranalysis of theGBMCNAdidnot
showanyassociationwithclinico-pathological features(datanot shown).
Log rank analysis of all altered regions across the GBM samples pointed
to the correlation of EGFR ampliﬁcation and/or gain of chr7 to better
survival of patients (P , 0.05, Figure 6).
In silico analysis
In order to validate our aCGH ﬁndings, TCGA analysis of 498 aCGH
samples extendedourGBMproﬁlingof theBrazilianpopulation (Figure
7). The most recurrent alterations were gain of chr7, chr19, chr20, and
chrX, as well as losses of chr9p, chr10, and chr13. Ampliﬁcation of
chr7p14.1-q11.21 was found in 226 cases (45.4%) and deletion in
9p22.1-p21.1 was found in 176 cases (59%). A small fraction of the
cases were found with deletion in chr10q23.2-q23.31 (25 cases - 5%),
while 417 cases (83.7%) presented a loss in this region.
Moreover, we extended our ﬁndings to the expression level. The
genes frequently found ampliﬁed/deleted in our GBM cases were in-
vestigated throughabioinformatics approach,using the compendiumof
cancer transcriptomeproﬁles (Oncomine).Once the list of genes encom-
passed in the ampliﬁed or deleted regions of our GBM samples was
generated,we inquiredwhether these genes had gain or loss of expression
in eight otherGBMexpressiondatasets (totaling 1489 tumor andnormal
brain samples).
More than half of the ampliﬁed genes, with concomitant over-
expression, were present in chr7p21.1-p11.2 (TWIST1, FERD3L,
TWISTNB, TMEM196,MACC1, ITGB8, SP8, SP4,DNAH11, CDCA7L,
RAPGEF5, IL6, FAM126A, KLHL7, NUPL2, GPNMB, C7orf30,
IGF2BP3, TRA2A, CCDC126, STK31, VWC2, FIGNL1, GRB10,
SEC61G, EGFR, LANCL2, SEPT14, ZNF713, GBAS, PSPH, CCT6A,
SUMF2, PHKG1, and CHCHD2), whereas 90.9% of the deleted genes,
presenting loss of expression were located at chr9p22.1-p21.3
(SLC24A2, MLLT3, KIAA1797, PTPLAD2, IFNB1, IFNW1, IFNA21,
IFNA4, IFNA7, IFNA17, IFNA14, IFNA5, IFNA6, IFNA13, IFNA8,
IFNA1, MTAP, CDKN2A, DMRTA1, and ELAVL2) (Table 6), sug-
gesting the potential importance of the genes present in these regions
in GBM development.
Considering these potentially important genes (Table 6),we found in
the TCGA expression dataset that the loss of expression of IFNA13,
IFNA21, IFNA6, IFNA8, IFNB1, IFNW1, or PTEN was correlated with
poor survival, whereas loss of expression ofGPNMB, IGF2BP3, ITGB8,
or SEC61G was correlated with better survival (Table 7). Additionally,
we found that there is an important positive correlation of expression
among the genes IFNB1, IFNA21, IFNW1, IFNA14, IFNA4, CDKN2A,
IFNA7, IFNA5, MTAP, IFNA17, IFNA1, IFNA6, IFNA13, IFNA8,
PTEN, BLOC1S1, SLC24A2, MYL6, PA2G2, CHCHD2, SP4, GDF11,
n Table 5 Percentage of cases, age at diagnosis and mean survival
of the patients divided in molecular groups based on 1p19q
deletion, TERT promoter and IDH1 mutational status
Molecular
Feature
Percentage
of Cases
Age at
Diagnosis (Years)
Mean Survival
(Months)
Triple positive 1.8 42 55
IDH1 only 22.8 38.8 29.2
TERT only 49.1 59.9 8.5
Triple negative 26.3 43.5 21.3
Triple positive represents 1p19q deletion + mutation in TERT promoter and
IDH1; Triple negative represents none of the three alterations.
Figure 5 Survival curve considering the patients presenting only IDH1
mutation, only TERTmutation, and neither mutation in IDH1 nor TERT,
nor loss of 1p19q (triple negative).
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and CAPA2. Furthermore, there is an important negative correlation of
these geneswithCS, ITGA7, SMARCC2,RAPGEF5, andKDR (Figure 8).
Finally, DAVID analysis showed that there are several functional
annotation clusters with a high enrichment score related to potentially
important biological processes, such as posttranscriptional regulation
of gene expression, regulation of translation, regulation of cell prolifera-
tion, and the transmembrane receptor protein tyrosine kinase signaling
pathway (Figure 9A). KEGG canonical pathways with a high number of
genes include the Jak-STAT signaling pathway, alongside pathways re-
lated to the immune response, glioma, and prostate cancer (Figure 9B).
DISCUSSION
In thepresent study,weperformedamolecular characterization inorder
to describe the genomic alterations andmutation status of the keyTERT
and IDH1 genes in astrocytomas arising in the Brazilian population.
Overall, the CNAs found in our aCGH analysis correspond to the
alterations found in the TCGA datasets. We found that 85.7% of the
GBMs presented gain of whole chr7, and 33.3% presented ampliﬁcation
in the region 7p12.2-p11.2, in which EGFR is included. The PTEN
tumor suppressor gene loci exhibited loss in 88.1% of our samples.
From the 42 GBM samples, only one did not present alterations in
chr7 and/or chr10, showing the importance of these loci in glioma-
genesis. Log rank analysis showed that our patients presenting EGFR
ampliﬁcation and/or chr7 gain had better overall survival than patients
that did not present these alterations. This ﬁnding is in accordance with
Smith et al. (2001) and Verhaak et al. (2010), who subdivided the
GBMs into four groups and found that patients with the ‘classical’
subtype, characterized by EGFR ampliﬁcation and chr10 loss, presented
better overall survival when they receive an intensive therapy (concur-
rent chemo- and radiotherapy or more than three subsequent cycles of
chemotherapy).
By analyzing the TCGA expression dataset, we found several other
genes correlatedwith overall survival. In order to determine the possible
interference of the coexpression of the genes in these results, we
performed correlation tests in potentially important genes in GBM
development. More than half of the genes that were statistically signif-
icant were located on 9p22.1-p21.3. This locus a frequent target of
homozygous deletion during gliomagenesis, and this event was ob-
served in more than half of our patients. This region encompasses
theCDKN2A tumor suppressor gene (p16INK4a/p14ARF/p15INK4b locus),
a potent regulator of the cell cycle (Li et al. 2011). Of interest, the chr13q
region encompassing the RB1 gene presented a loss in 57.1% of our
GBM samples. Previous studies have reported that homozygous de-
letion of p16INK4a, CDK4 ampliﬁcation, and loss of RB1 are almost
mutually exclusive (Verhaak et al. 2010; Ohgaki and Kleihues 2009),
and that these alterations are found in50%of primaryGBMs (Ohgaki
and Kleihues 2009).
We have previously determined MSI status in 144 gliomas (71
children and young people and 73 adults). Of the 14 gliomas that were
from patients of Brazilian origin, all of them were , 18 years of age
(Viana-Pereira et al. 2011). Overall, a total of 13.2% of the samples
presentedMSI, inwhich themajority was pediatric (P= 0.02, Chi-square
Figure 6 Survival curves of the patients consid-
ering (A) EGFR ampliﬁcation and (B) chromosome
7 gain.
Figure 7 Frequency plot representing the gained and lost regions in The Cancer Genome Atlas (TCGA) glioblastoma dataset.
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test). Similar to the ﬁndings of the present work, all the adult MSI-
positive cases previously reportedwereGBMs (Viana-Pereira et al. 2011).
Recurrent mutations in the promoter region of TERT gene, namely
the c.-146:C . T and the c.-124:C . T mutations, were recently re-
ported in several tumors, including melanomas, bladder, hepatocarci-
noma, thyroid carcinomas, and gliomas (Huang et al. 2013; Vinagre
et al. 2013; Killela et al. 2013; Horn et al. 2013; Bell et al. 2015; Batista
et al. 2016). Thesemutations generate a consensus binding site for ETS/
TCF transcription factors (CCGGAA), resulting in increased activity of
the TERT promoter and abnormal telomere size maintenance (Huang
et al. 2013; Vinagre et al. 2013; Killela et al. 2013; Horn et al. 2013; Bell
et al. 2015; Cancer Genome Atlas Research Network et al. 2015; Eckel-
Passow et al. 2015; Koelsche et al. 2013). In accordance, we found a low
percentage of pilocytic, diffuse, and anaplastic astrocytomas presenting
mutations in the TERT promoter gene. Additionally, we found a high
percentage of GBMs presenting either the mutation -124:G . A
(52.6%) or -146:G . A (21.1%), which shows the importance of this
mutation to GBM development, since it constitutively activates the
TERT gene, supporting the maintenance of genomic integrity through
telomere elongation (Heidenreich et al. 2014; Walsh et al. 2015).
By analyzing an important dataset of gliomas, Ceccarelli et al. (2016)
described distinct glioma subgroups based on methylation and gene
expression status, and correlated them with survival, grade, and age at
diagnosis. Based on DNA methylation analysis, the authors described
six clusters: three clusters presented IDHmutations and were enriched
for low-grade gliomas, whereas the clusters with wild-type IDH were
enriched for GBMs. In fact, we found 77.8% (7/9) of diffuse and 100%
(7/7) of anaplastic astrocytomas presenting IDH1 mutation, whereas
92.9% (3/42) of GBMs were wild-type for IDH1mutation, corroborat-
ing this data. Independent of the tumor grade, we also found a dramatic
increase in survival in patients presenting IDH1 mutation (29.2
months), suggesting that this gene is an important biomarker, as the
authors have previously found that IDHmutation was the main driver
of the clusters (Ceccarelli et al. 2016).
Similarly, other comprehensive studies suggest that the combined
analysis of themutational status ofTERT, IDH, and 1p/19qdeletionhad
the ability to deﬁne the biological and clinical behavior of gliomas better
than analysis based solely in histology (Foote et al. 2015; Eckel-Passow
et al. 2015). When we performed this stratiﬁcation in our samples, we
found that the group presenting onlyTERTmutation had a dramatically
reduced survival of 8.5 months vs. 29.2 months of only IDH1-mutated
patients. This is consistent with recent data that showed an association
of TERTmutation with poor survival, and that of IDH1mutation with
better survival (Eckel-Passow et al. 2015; Foote et al. 2015). Generally,
mean age at diagnosis in our groupswas also consistentwith the literature,
with elderly patients presenting only TERTmutation (Eckel-Passow et al.
2015).
Besides the alterations in the genes extensively studied in GBMs,
there may exist some less-studied regions/genes that could help in the
understandingofGBMdevelopment and/or couldbepotential targets in
GBM treatment. To identify these genes, we selected those present in
regions frequently ampliﬁedor deleted in ourGBMs and exploring their
expression in Oncomine datasets. Hodgson et al. (2009) assessed the
gene expression data of TCGA-derived GBMs and found overexpres-
sion of genes related to cellular assembly and organization and, among
other genes, the authors found CDK2 (located at 12q13), which was
found ampliﬁed in four of our GBM samples. In fact, this gene interacts
with others (found overexpressed in TCGA-derived samples), such as
AURKB, BIRC5, CCNB1, CCNB2, CDC2, and FOXM1, and forms a
transcriptional network important for G2/Mprogression and/or check-
point activation (Hodgson et al. 2009). Still related to cell proliferation
and differentiation, DMRTA1 (chr9p21.3) and DMRTA2 (chr1p32.3)
were found deleted in 21 and two samples, respectively. These genes are
highly expressed in the early developing telencephalon of rodent embryos
(Kikkawa et al. 2013; Konno et al. 2012). Studies show that DMRTA1
n Table 6 Ampliﬁed genes that presented overexpression and deleted genes that presented decreased expression in Oncomine datasets
Event Region Genes
Amp/Overexp 4q11-q12 LRRC66, SGCB, SPATA18, SCFD2, CHIC2, PDGFRA, KDR
Amp/Overexp 7p21.1-p15.3 TWIST1, FERD3L, TWISTNB, TMEM196, MACC1, ITGB8, SP8, SP4,
DNAH11, CDCA7L, RAPGEF5, IL6, FAM126A, KLHL7, NUPL2,
GPNMB, C7orf30, IGF2BP3, TRA2A, CCDC126, STK31
Amp/Overexp 7p12.2-p11.2 VWC2, FIGNL1, GRB10, SEC61G, EGFR, LANCL2, SEPT14, ZNF713,
GBAS, PSPH, CCT6A, SUMF2, PHKG1, CHCHD2
Amp/Overexp 7q31.2 CAV2, CAV1, CAPZA2
Amp/Overexp 12q13.2-q13.3 OR6C1, OR6C68, OR6C4, OR10P1, ITGA7, BLOC1S1, GDF11, SARNP,
DNAJC14, WIBG, CDK2, PA2G4, FAM62A, MYL6, SMARCC2,
ANKRD52, CS
Amp/Overexp 12q14.3-q15 CAND1, DYRK2
Del/LOexp 9p22.1-p21.3 SLC24A2, MLLT3, KIAA1797, PTPLAD2, IFNB1, IFNW1, IFNA21, IFNA4,
IFNA7, IFNA17, IFNA14, IFNA5, IFNA6, IFNA13, IFNA8, IFNA1,MTAP,
CDKN2A, DMRTA1, ELAVL2
Del/LOexp 10q23.2-q23.31 ATAD1, PTEN
Amp, ampliﬁcation in GBM samples; Overexp, overexpression in Oncomine samples; Del, deletion in GBM samples; LOexp, loss of expression in Oncomine samples.
n Table 7 Genes correlated to overall survival in the GBM samples
Gene Genome Location Log Rank P Value
IFNA13a 9p22.1-p21.3 0.039
IFNA21a 9p22.1-p21.3 0.01
IFNA6a 9p22.1-p21.3 0.016
IFNA8a 9p22.1-p21.3 0.002
IFNB1a 9p22.1-p21.3 0.007
IFNW1a 9p22.1-p21.3 0.002
GPNMBb 7p21.1-p15.3 0.008
IGF2BP3b 7p21.1-p15.3 0.008
ITGB8b 7p21.1-p15.3 0.023
SEC61Gb 7p12.2-p11.2 0.000025
PTENa 10q23.2-q23.31 0.006
a
Genes for which the loss of expression was correlated to poor survival.
b
Genes for which the loss of expression was correlated to better survival.
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is a downstream gene of PAX6, a potent regulator of proliferation and
differentiation of neural stem/progenitor cells. Once expressed,DMRTA1
(together with DMRTA3) promotes neuronal differentiation via regula-
tion of NEUROG2 (Kikkawa et al. 2013). On the other hand, DMRTA2
plays pivotal roles in the early development of the telencephalon via for-
mation of the cortical hem, a source of Wnts, and by maintaining neural
progenitors as a downstream target of theWntpathway (Konno et al. 2012).
The MTAP gene was codeleted with CDKN2A in 21 GBMs. The
protein coded byMTAP cleavesMTA (generated during polyamine bio-
synthesis) in adenine, and it is converted to AMP and 5-metiltioribose-1-
phosphate. Then, 5-metiltioribose-1-phosphate is converted tomethionine
(Bertino et al. 2011). Therefore, this protein is responsible for the
recycling of adenine andmethionine in the normalmetabolism (Bertino
et al. 2011). The role of MTAP in gliomas is poorly characterized. High
frequency of MTAP deletion has been described in high-grade
gliomas (Sasaki et al. 2003), namely in GBMs (Nakahara et al. 2004;
Suzuki et al. 2004), in agreement with the present study, and also our
recent report of MTAP protein expression in more than 85% of
pilocytic astrocytomas (Becker et al. 2015b). Other studies have re-
ported that homozygous deletion of MTAP is highly associated with
loss of expression (Crespo et al. 2012), and that its expression is
associated with lifetime- and progression-free survival in GBMs
(Serao et al. 2011). Interestingly, we previously described thatMTAP
expression is possibly disrupted through intragenic breakpoints in
pediatric high-grade gliomas (Carvalho et al. 2014).
Through bioinformatics approaches, we found that a family of
several interferon (IFN) genes are coexpressed with MTAP and
CDKN2A. In fact, these genes are located at the same cytoband and
Figure 8 Correlation of the expression in TGCA The Cancer Genome Atlas dataset considering the genes deleted or ampliﬁed in our datasets.
The crosses indicate that there was no statistical difference in the correlation.
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frequently deleted in GBM. Exogenous IFN has been used for biother-
apy in several malignancies (Dillman 2011), since IFN treatment may
induce apoptosis in tumor cells (Sgorbissa et al. 2011). Additionally,
studies have evaluated the contribution of autocrine IFN production in
the apoptotic response to IFNa in U87MG and T98G cells. They found
that endogenous IFN production is responsible for sustaining high
levels of TRAIL, and that loss of IFN genes confers an adaptive advan-
tage to cancer cells, since they confer resistance to IFNa-induced apo-
ptosis (Sgorbissa et al. 2011). In line with this, we found in the TCGA
dataset that loss of expression of IFNA13, IFNA21, IFNA6, IFNA8,
Figure 9 DAVID clustering analy-
sis showing (A) functional annota-
tion clustering based on biological
processes and (B) Kyoto Encyclope-
dia of Genes and Genomes (KEGG)
functional annotation. DAVID, The
Database for Annotation, Visualiza-
tion, and Integrated Discovery.
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IFNB1, or IFNW1 was correlated to poor survival, increasing the evi-
dence for the importance of the tumor-stroma microenvironment in-
teraction in gliomagenesis.
Despite the extensive molecular characterizations published
worldwide, all patients are been treated using the same standard
protocols and the outcome of high-grade gliomas remains poor
(Malmstrom et al. 2012). To date, there are very few predictive
biomarkers, with MGMT methylation status the only one to have
been accepted by consensus and in clinical use (Hegi et al. 2005;
Malmstrom et al. 2012). In 2014, the International Society of
Neuropathology recommended, in the “ISN-Haarlem Consensus
Guidelines,” the support of molecular analysis in the determination
of tumor entities (Louis et al. 2014), showing the emerging impor-
tance of molecular analyses in diagnosis.
In conclusion, we performed, for the ﬁrst time, an integrated
characterization of chromosomal CNA, microsatellite instability,
and TERT/IDH1 mutational analysis in astrocytomas arising in the
Brazilian population. Besides the expected similar pattern of alter-
ations described worldwide, the combination of our ﬁndings with in
silico analysis of the Oncomine and TCGA data has led to the iden-
tiﬁcation of genes for further investigation in glioma, such as CDK2,
DMRTA1, MTAP, and IFN. This study contributes to the molecular
proﬁling of astrocytomas, and constitutes an important step towards
future personalized medical approaches for the treatment of patients
diagnosed with astrocytomas.
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